SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Celera Genomics (CRA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob zagorin who wrote (481)7/9/2000 9:07:55 AM
From: Biotech Jim  Read Replies (1) of 746
 
Bob-

I have been doing further DD on the genomics companies, and there is no doubt in my mind that CRA is THE genome sequencing powerhouse. Their work on melanogaster was outstanding, as well as their jamborees for drosophila genome encoded genes annotation efforts. But, I do have a question concerning their human genome work. Due to the high ratio of intron to exon sequences in the human genome, I wonder how good are the exon prediction alogorithms that CRA uses. I am led to believe that this technology throughout the public sector, private sector and in academia is not sufficient for the task at hand. Do you (or others) have any thoughts on this? Do you suspect that this is why the HHMI granted membership to Phil Green into this esteemed community, to improve on the current algorithms?

Disclosure: I am neither long or short CRA or INCY at the present time.
BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News